Physician profile
Tanner Cavanaugh
NPI 1811394976
$5,582.33
in general payments reported to CMS, 2019-2025
19 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $529 · 2022: $1,230 · 2023: $1,626 · 2024: $1,752 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,807 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,806.61 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $910.57 | 2021-2025 | |
| Janssen Biotech, INC. | $879.12 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $664.24 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $649.16 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $571.41 | 2021-2025 | Dupixent |
| Kerecis Limited | $466.68 | 2021-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Incyte Corporation | $265.86 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $235.75 | 2024-2025 | Nemluvio |
| Ucb, INC. | $189.53 | 2023-2025 | Bimzelx, Cimzia, Briviact |
| Leo Pharma INC. | $151.02 | 2022-2024 | Adbry |
| Amgen INC. | $120.43 | 2023-2025 | Otezla |
| Arcutis Biotherapeutics, INC. | $119.22 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $83.18 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $76.88 | 2021-2024 | Ebglyss, Taltz |
| Janssen Scientific Affairs, LLC | $68.62 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $53.44 | 2023-2024 | |
| Dermavant Sciences, INC. | $43.43 | 2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $27.90 | 2022 | |
| Organon LLC | $5.89 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanner Cavanaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.